Business Standard

Dr Reddy's plans new brands in Russia, says no issue with funds in country

The company's Russian revenue was at Rs 686 crore for Q4FY22, a year-on-year growth of 70%.

DRDO’s 2DG anti-Covid drug priced at Rs 990 per sachet: Dr Reddy's
Premium

Sohini Das Mumbai
Dr Reddy’s Laboratories (DRL) continues to focus on Russia, where it grew its market share in financial year 2021-22 (FY22), and plans to launch new brands there. As for Ukraine, the company is trying to deliver medicines and is working out logistics solutions, the firm said.

Speaking to the media after the quarterly results, GV Prasad, co-chairman and managing director of DRL, said: “Our Russian operations continue as usual. There was some stocking up of inventory by our customers during the initial period of this ongoing crisis. From the next quarter we expect that to normalise.” He added that the firm

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 19 2022 | 5:20 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com